Lorena M Amaral1, Luissa Kiprono2, Denise C Cornelius1, Carrie Shoemaker1, Kedra Wallace3, Janae Moseley1, Gerd Wallukat4, James N Martin2, Ralf Dechend4, Babbette LaMarca5. 1. Department of Pharmacology, University of Mississippi Medical Center, Jackson, MS. 2. Division of Maternal-Fetal Medicine, University of Mississippi Medical Center, Jackson, MS. 3. Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS. 4. Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine, Helios Clinic, Berlin, Germany. 5. Department of Pharmacology, University of Mississippi Medical Center, Jackson, MS; Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS. Electronic address: bblamarca@umc.edu.
Abstract
OBJECTIVE: Preeclampsia is a multisystem disorder recognized as hypertension with proteinuria developing >20 weeks' gestation. Preeclampsia is associated with chronic immune activation characterized by increased T and B lymphocytes, cytokines, and antibodies activating the angiotensin II type I receptor (AT1-AA). Hypertension in response to elevated interleukin (IL)-6 during pregnancy occurs with increased renin activity and AT1-AA, and reduced kidney function. STUDY DESIGN: We aim to determine whether 17-alpha-hydroxyprogesterone caproate (17-OHPC), progesterone, improved inflammatory pathways during elevated IL-6 in pregnant rats. IL-6 (5 ng/d) was infused via miniosmotic pumps into normal pregnant (NP) rats beginning on day 14 of gestation and 17-OHPC (3.32 mg/kg) was diluted in normal saline and injected on day 18. Blood pressure (mean arterial pressure [MAP]) determination and serum collection were performed on day 19 of gestation. RESULTS: MAP in NP was 100 ± 3 mm Hg, which increased with IL-6 to 112 ± 4 mm Hg (P < .05). Pregnant rats given 17-OHPC alone had a MAP of 99 ± 3 mm Hg and MAP increased to 103 ± 2 mm Hg in IL-6+17-OHPC. AT1-AA was 1.2 ± 0.5 bpm in NP rats, increased to 17 ± 9 bpm with IL-6 infusion but administration of 17-OHPC significantly blunted AT1-AA to 4 ± 0.8 bpm in NP+IL-6+17-OHPC. Total circulating nitrate/nitrite was significantly decreased and placental Ser(1177)-phosporylated-eNOS/eNOS was lowered with IL-6 infusion. Supplementation of 17-OHPC significantly improved placental Ser(1177)-phosporylated-eNOS/eNOS however, circulating nitrate/nitrite was unchanged with 17-OHPC supplementation. CONCLUSION: This study illustrates that 17-OHPC attenuated hypertension, decreased AT1-AA activity, and improved placental nitric oxide in response to elevated IL-6 during pregnancy and could lend hope to a new potential therapeutic for preeclampsia.
OBJECTIVE: Preeclampsia is a multisystem disorder recognized as hypertension with proteinuria developing >20 weeks' gestation. Preeclampsia is associated with chronic immune activation characterized by increased T and B lymphocytes, cytokines, and antibodies activating the angiotensin II type I receptor (AT1-AA). Hypertension in response to elevated interleukin (IL)-6 during pregnancy occurs with increased renin activity and AT1-AA, and reduced kidney function. STUDY DESIGN: We aim to determine whether 17-alpha-hydroxyprogesterone caproate (17-OHPC), progesterone, improved inflammatory pathways during elevated IL-6 in pregnant rats. IL-6 (5 ng/d) was infused via miniosmotic pumps into normal pregnant (NP) rats beginning on day 14 of gestation and 17-OHPC (3.32 mg/kg) was diluted in normal saline and injected on day 18. Blood pressure (mean arterial pressure [MAP]) determination and serum collection were performed on day 19 of gestation. RESULTS: MAP in NP was 100 ± 3 mm Hg, which increased with IL-6 to 112 ± 4 mm Hg (P < .05). Pregnant rats given 17-OHPC alone had a MAP of 99 ± 3 mm Hg and MAP increased to 103 ± 2 mm Hg in IL-6+17-OHPC. AT1-AA was 1.2 ± 0.5 bpm in NP rats, increased to 17 ± 9 bpm with IL-6 infusion but administration of 17-OHPC significantly blunted AT1-AA to 4 ± 0.8 bpm in NP+IL-6+17-OHPC. Total circulating nitrate/nitrite was significantly decreased and placental Ser(1177)-phosporylated-eNOS/eNOS was lowered with IL-6 infusion. Supplementation of 17-OHPC significantly improved placental Ser(1177)-phosporylated-eNOS/eNOS however, circulating nitrate/nitrite was unchanged with 17-OHPC supplementation. CONCLUSION: This study illustrates that 17-OHPC attenuated hypertension, decreased AT1-AA activity, and improved placental nitric oxide in response to elevated IL-6 during pregnancy and could lend hope to a new potential therapeutic for preeclampsia.
Authors: Sowndramalingam Sankaralingam; Ivan A Arenas; Manoj M Lalu; Sandra T Davidge Journal: Expert Rev Mol Med Date: 2006-01-26 Impact factor: 5.600
Authors: Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel Journal: Cell Mol Life Sci Date: 2009-03-31 Impact factor: 9.261
Authors: G Wallukat; V Homuth; T Fischer; C Lindschau; B Horstkamp; A Jüpner; E Baur; E Nissen; K Vetter; D Neichel; J W Dudenhausen; H Haller; F C Luft Journal: J Clin Invest Date: 1999-04 Impact factor: 14.808
Authors: Valeria C Sandrim; Marcelo F Montenegro; Ana C T Palei; Ingrid F Metzger; Jonas T C Sertorio; Ricardo C Cavalli; Jose E Tanus-Santos Journal: Free Radic Biol Med Date: 2010-05-25 Impact factor: 7.376
Authors: Jamil T Elfarra; Jesse N Cottrell; Denise C Cornelius; Mark W Cunningham; Jessica L Faulkner; Tarek Ibrahim; Babbette Lamarca; Lorena M Amaral Journal: Pregnancy Hypertens Date: 2019-12-02 Impact factor: 2.899
Authors: Meghan H Pearl; Richard K Leuchter; Elaine F Reed; Qiuheng Zhang; Robert B Ettenger; Eileen W Tsai Journal: Pediatr Nephrol Date: 2015-05-09 Impact factor: 3.714
Authors: Martijn F Hoes; Zoltan Arany; Johann Bauersachs; Denise Hilfiker-Kleiner; Mark C Petrie; Karen Sliwa; Peter van der Meer Journal: Nat Rev Cardiol Date: 2022-01-11 Impact factor: 49.421
Authors: Babbette LaMarca; Denise C Cornelius; Ashlyn C Harmon; Lorena M Amaral; Mark W Cunningham; Jessica L Faulkner; Kedra Wallace Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-04-20 Impact factor: 3.619
Authors: Jenna N Parrish; Megan L Bertholomey; Hong W Pang; Robert C Speth; Mary M Torregrossa Journal: Transl Psychiatry Date: 2019-01-29 Impact factor: 6.222